Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 4/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 8/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922140 | 1.00 | CXCR4 (0.49) | CXCR4ITGB3ITGAVTAS2R14GAA | |
| SCHEMBL14025428 | 0.91 | ITGB3 (0.45) | ITGB3ITGAVTAS2R14GAASMN1; SMN2 | |
| SCHEMBL4786868 | 0.83 | CXCR4 (0.54) | CXCR4SLC40A1 | |
| SCHEMBL4916980 | 0.81 | KMT2A (0.53) | CXCR4SMN1; SMN2 | |
| SCHEMBL4921023 | 0.77 | CXCR4 (0.50) | CXCR4GAASMN1; SMN2SLC40A1CA2 | |
| SCHEMBL13909540 | 0.76 | CXCR4 (0.58) | CXCR4GAASLC40A1 | |
| SCHEMBL14025562 | 0.76 | CXCR4 (0.47) | CXCR4ITGB3ITGAVGAASMN1; SMN2 | |
| SCHEMBL4922749 | 0.76 | CXCR3 (0.47) | CXCR4GAASMN1; SMN2HSD17B10 | |
| SCHEMBL4913474 | 0.74 | ALDH1A1 (0.55) | TAS2R14GAASMN1; SMN2HSD17B10 | |
| SCHEMBL4926200 | 0.74 | KCNA5 (0.45) | CXCR4SLC40A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | CXCR4 242/4885ITGB3 1571/4885ITGAV 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.